Anúncio
Anúncio

XFOR

XFOR logo

X4 Pharmaceuticals, Inc. Common Stock

3.97
USD
Patrocinado
+0.13
+3.41%
06 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

3.97

0.00
-0.03%

Relatórios de Lucros XFOR

Rácio de surpresa positiva

XFOR separação 17 de 31 últimas estimativas.

55%

Próximo Relatório

Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.77M
/
-$0.38
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+0.15%
/
-44.93%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+23.27%
/
-93.67%

X4 Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 05 de nov. de 2025, XFOR reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.93 USD, resulting in a 26.15% surprise. Revenue reached 1.76 milhão, compared to an expected 2.08 milhão, with a -15.25% difference. The market reacted with a -10.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.38 USD, with revenue projected to reach 1.77 milhão USD, implying an diminuir of -44.93% EPS, and aumentar of 0.15% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, X4 Pharmaceuticals, Inc. Common Stock reported EPS of -$0.69, beating estimates by 26.15%, and revenue of $1.76M, -15.25% below expectations.
The stock price moved down -10.58%, changed from $3.97 before the earnings release to $3.55 the day after.
The next earning report is scheduled for 23 de mar. de 2026.
Based on 6 analistas, X4 Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $1.77M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio